Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma

PARP inhibitors are mainly used to treat BRCA1/2 mutated cancers. Here, the authors show that MYC amplified glioblastomas are sensitive to PARP inhibition due to CDK18 repression, which impairs ATR regulated homologous recombination repair, and that ATR inhibition sensitises glioblastomas to PARP in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jian-Fang Ning, Monica Stanciu, Melissa R. Humphrey, Joshua Gorham, Hiroko Wakimoto, Reiko Nishihara, Jacqueline Lees, Lee Zou, Robert L. Martuza, Hiroaki Wakimoto, Samuel D. Rabkin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/403bcdc87a4246559e313ab4b0cb3355
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:403bcdc87a4246559e313ab4b0cb3355
record_format	dspace
spelling	oai:doaj.org-article:403bcdc87a4246559e313ab4b0cb33552021-12-02T17:32:10ZMyc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma10.1038/s41467-019-10993-52041-1723https://doaj.org/article/403bcdc87a4246559e313ab4b0cb33552019-07-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-10993-5https://doaj.org/toc/2041-1723PARP inhibitors are mainly used to treat BRCA1/2 mutated cancers. Here, the authors show that MYC amplified glioblastomas are sensitive to PARP inhibition due to CDK18 repression, which impairs ATR regulated homologous recombination repair, and that ATR inhibition sensitises glioblastomas to PARP inhibition.Jian-Fang NingMonica StanciuMelissa R. HumphreyJoshua GorhamHiroko WakimotoReiko NishiharaJacqueline LeesLee ZouRobert L. MartuzaHiroaki WakimotoSamuel D. RabkinNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-18 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Jian-Fang Ning Monica Stanciu Melissa R. Humphrey Joshua Gorham Hiroko Wakimoto Reiko Nishihara Jacqueline Lees Lee Zou Robert L. Martuza Hiroaki Wakimoto Samuel D. Rabkin Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
description	PARP inhibitors are mainly used to treat BRCA1/2 mutated cancers. Here, the authors show that MYC amplified glioblastomas are sensitive to PARP inhibition due to CDK18 repression, which impairs ATR regulated homologous recombination repair, and that ATR inhibition sensitises glioblastomas to PARP inhibition.
format	article
author	Jian-Fang Ning Monica Stanciu Melissa R. Humphrey Joshua Gorham Hiroko Wakimoto Reiko Nishihara Jacqueline Lees Lee Zou Robert L. Martuza Hiroaki Wakimoto Samuel D. Rabkin
author_facet	Jian-Fang Ning Monica Stanciu Melissa R. Humphrey Joshua Gorham Hiroko Wakimoto Reiko Nishihara Jacqueline Lees Lee Zou Robert L. Martuza Hiroaki Wakimoto Samuel D. Rabkin
author_sort	Jian-Fang Ning
title	Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
title_short	Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
title_full	Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
title_fullStr	Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
title_full_unstemmed	Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
title_sort	myc targeted cdk18 promotes atr and homologous recombination to mediate parp inhibitor resistance in glioblastoma
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/403bcdc87a4246559e313ab4b0cb3355
work_keys_str_mv	AT jianfangning myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT monicastanciu myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT melissarhumphrey myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT joshuagorham myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT hirokowakimoto myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT reikonishihara myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT jacquelinelees myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT leezou myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT robertlmartuza myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT hiroakiwakimoto myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma AT samueldrabkin myctargetedcdk18promotesatrandhomologousrecombinationtomediateparpinhibitorresistanceinglioblastoma
_version_	1718380363095474176

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma

Ejemplares similares